Companion diagnostics

Industry and regulators collaborate to harmonize or consolidate PD-1/PDL-1 assays

How liquid biopsy and next-generation sequencing fit into the pathology lab of the future

Anthony Whetton, Director of the Stoller Biomarker Discovery Centre, Manchester, UK

FDA issues first-ever approval for liquid biopsy companion diagnostic

Digital pathology and tissue image analysis tools are essential to developing companion diagnostics and enabling pathologists to support clinical decisions, but there is still work to be done…

What does analysis of the last five years of literature on companion diagnostics tell us about the priorities of the field, and the contributors to it?

Keith Miller is Director and co-founder of CADQAS (Cancer Diagnostic Quality Assurance Services), a not-for-profit community interest company hosted by Poundbury Cancer Institute (PCI).

Christopher Hudson is Director of Tissue Diagnostics UK and Ireland at Roche, the multinational life sciences company that supports the Poundbury Cancer Institute through funding and research collaboration.

Poundbury Cancer Institute aims to put pathology at the forefront of cancer research, and bring industry, national healthcare service and quality assurance together to expand the use of companion diagnostics and important biological markers.

At the Poundbury Cancer Center, pathology, business and quality assurance are uniting to create a cutting-edge home for companion diagnostics.